292 related articles for article (PubMed ID: 31980914)
1. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
2. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
4. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
[TBL] [Abstract][Full Text] [Related]
5. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
[TBL] [Abstract][Full Text] [Related]
7. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
9. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
Uenaka A; Wada H; Isobe M; Saika T; Tsuji K; Sato E; Sato S; Noguchi Y; Kawabata R; Yasuda T; Doki Y; Kumon H; Iwatsuki K; Shiku H; Monden M; Jungbluth AA; Ritter G; Murphy R; Hoffman E; Old LJ; Nakayama E
Cancer Immun; 2007 Apr; 7():9. PubMed ID: 17441676
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.
Mahipal A; Ejadi S; Gnjatic S; Kim-Schulze S; Lu H; Ter Meulen JH; Kenney R; Odunsi K
Cancer Immunol Immunother; 2019 Jul; 68(7):1211-1222. PubMed ID: 31069460
[TBL] [Abstract][Full Text] [Related]
11. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Nagata Y; Kageyama S; Ishikawa T; Kokura S; Okayama T; Abe T; Murakami M; Otsuka K; Ariyoshi T; Kojima T; Taniguchi K; Kobayashi S; Shimada H; Yajima S; Suzuki T; Hirano S; Tsuchikawa T; Shichinohe T; Ueda S; Kanetaka K; Yoneda A; Wada H; Doki Y; Yamaue H; Katsuda M; Ohi M; Yasuda H; Kondo K; Kataoka M; Kodera Y; Koike M; Shiraishi T; Miyahara Y; Goshima N; Fukuda E; Yamaguchi K; Sato E; Ikeda H; Yamada T; Osako M; Hirai K; Miyamoto H; Watanabe T; Shiku H
Cancer Immunol Immunother; 2022 Nov; 71(11):2743-2755. PubMed ID: 35429246
[TBL] [Abstract][Full Text] [Related]
13. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.
Somaiah N; Block MS; Kim JW; Shapiro GI; Do KT; Hwu P; Eder JP; Jones RL; Lu H; Ter Meulen JH; Bohac C; Chen M; Hsu FJ; Gnjatic S; Pollack SM
Clin Cancer Res; 2019 Oct; 25(19):5808-5817. PubMed ID: 31227504
[TBL] [Abstract][Full Text] [Related]
14. Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1.
Harada N; Hoshiai K; Takahashi Y; Sakaguchi Y; Kuno T; Hishida T; Shiku H
Kobe J Med Sci; 2008 May; 54(1):E23-34. PubMed ID: 18772606
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
16. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
Bender A; Karbach J; Neumann A; Jäger D; Al-Batran SE; Atmaca A; Weidmann E; Biskamp M; Gnjatic S; Pan L; Hoffman E; Old LJ; Knuth A; Jäger E
Cancer Immun; 2007 Oct; 7():16. PubMed ID: 17944437
[TBL] [Abstract][Full Text] [Related]
17. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
18. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
[TBL] [Abstract][Full Text] [Related]
19. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
[TBL] [Abstract][Full Text] [Related]
20. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
